Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07104032 · ClinicalTrials.gov registry record · Phase 3
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
A Phase 3 study of Relapsed/Refractory Primary Central Nervous System Lymphoma, sponsored by Ono Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 132
- Enrollment target
- 4
- Study locations
NCT07104032 is a Phase 3 study of Relapsed/Refractory Primary Central Nervous System Lymphoma that is actively recruiting participants, run by Ono Pharmaceutical Co.. The registered enrollment target is 132 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT07104032, a Phase 3 study of Relapsed/Refractory Primary Central Nervous System Lymphoma, is actively recruiting participants, sponsored by Ono Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 132 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Temozolomide
- DRUG Tirabrutinib
Study Locations (4)
Arizona
- HonorHealth Cancer Center - Scottsdale
Connecticut
- Yale Cancer Center - New Haven
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2026-03 |
| Est. Completion | 2029-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07104032
The ClinicalTrials.gov registry entry for NCT07104032 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharmaceutical Co., which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Primary Central Nervous System Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Rituximab is the first listed.
NCT07104032 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Connecticut, New York.
Frequently Asked Questions
What is clinical trial NCT07104032 about?
NCT07104032 is a clinical study titled "IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)". The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).
What is the current status of trial NCT07104032?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 132 participants. The study started on 2026-03. Estimated completion is 2029-12.
What conditions does trial NCT07104032 study?
This clinical trial studies the following conditions: Relapsed/Refractory Primary Central Nervous System Lymphoma.
What interventions are being tested in trial NCT07104032?
The interventions under investigation include: Rituximab (DRUG), Temozolomide (DRUG), Tirabrutinib (DRUG).
Who is sponsoring clinical trial NCT07104032?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07104032 being conducted?
This trial has 4 study locations across Arizona, Connecticut, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.